Login to Your Account



FDA Panel Backs Gilead Drug For Treating Chronic Hepatitis B

By Kim Coghill


Wednesday, August 7, 2002
BETHESDA, Md. - An FDA panel of experts unanimously recommended approval of Gilead Sciences Inc.'s once-daily tablet, adefovir dipivoxil, for chronic hepatitis B. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription